In another study conducted on 253 patients with type 2 diabetes, the patients were stratified into two groups: patients receiving sitagliptin (a DPP-4 inhibitor) + metformin and/or insulin treatment and patients receiving only metformin and/or insulin treatment. This evidence concerns the gene INS and type 2 diabetes mellitus.